bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report released on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

A number of other brokerages have also recently commented on BLUE. Wells Fargo & Company cut their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Barclays upped their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, December 31st. Finally, Baird R W lowered shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $51.00.

bluebird bio Stock Performance

Shares of bluebird bio stock opened at $3.90 on Thursday. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The stock has a market cap of $37.92 million, a price-to-earnings ratio of -0.10 and a beta of 0.76. The company’s fifty day moving average is $5.97 and its 200 day moving average is $8.00. bluebird bio has a twelve month low of $3.56 and a twelve month high of $28.60.

Institutional Investors Weigh In On bluebird bio

Institutional investors and hedge funds have recently made changes to their positions in the business. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of bluebird bio in the 4th quarter worth about $175,000. Verition Fund Management LLC purchased a new stake in bluebird bio in the 3rd quarter valued at about $42,000. Captrust Financial Advisors increased its stake in bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares during the last quarter. Barclays PLC increased its stake in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 184,605 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 355,562 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.